- Home
- BAH vs GH Comparison
BAH vs GH Comparison
Compare BAH & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BAH | GH |
|---|---|---|
| Founded | 1914 | 2011 |
| Country | United States | United States |
| Employees | 35800 | N/A |
| Industry | Professional Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7B | 13.3B |
| IPO Year | 2010 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BAH | GH |
|---|---|---|
| Price | $81.68 | $91.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 20 |
| Target Price | $105.20 | ★ $117.80 |
| AVG Volume (30 Days) | ★ 1.9M | 1.8M |
| Earning Date | 04-22-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.96% | N/A |
| EPS Growth | ★ 57.95 | 6.74 |
| EPS | ★ 5.22 | N/A |
| Revenue | ★ $11,980,000,000.00 | $982,021,000.00 |
| Revenue This Year | N/A | $29.73 |
| Revenue Next Year | $2.24 | $27.71 |
| P/E Ratio | $15.29 | ★ N/A |
| Revenue Growth | 12.36 | ★ 32.88 |
| 52 Week Low | $73.93 | $34.91 |
| 52 Week High | $130.91 | $120.74 |
Technical Indicators
Market Signals| Indicator | BAH | GH |
|---|---|---|
| Relative Strength Index (RSI) | 50.02 | 34.53 |
| Support Level | $79.23 | $90.44 |
| Resistance Level | $89.79 | $114.53 |
| Average True Range (ATR) | 2.78 | 5.70 |
| MACD | 0.70 | -0.84 |
| Stochastic Oscillator | 94.74 | 11.27 |
Price Performance
Historical ComparisonAbout BAH Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp provides technology solutions in areas such as artificial intelligence, cybersecurity, and related fields. The company serves U.S. federal government agencies, commercial clients, and select international customers. It also provides technologies to evolve defense missions and delivers solutions to warfighters in the digital battlespace.
About GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.